SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 30, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the ...
United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...
United Therapeutics Corporation UTHR shares are up during Monday’s premarket session following the announcement that the ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR) announced today that it will host a webcast to review data from the successful TETON-2 ...
Interstitial lung disease (ILD) refers to a group of conditions that cause damage and stiffness in the lung tissue. Over time, this damage can make it harder for oxygen to move into the bloodstream.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...
Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Subjects will be randomly allocated 1:1 to receive Tyvaso or placebo. All subjects will initiate Tyvaso or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results